Before Eli Lilly Stock Skyrocketed, Main Street Could Already See the Parking Lots Full

Gallup data showed demand before the stock made it obvious

The clearest early signal was simple: more people were actually taking the drugs. Before Eli Lilly traded near $1,222, Gallup found that 11% of U.S. adults were currently taking GLP-1 medications, up from 3% in 2024, while about 9 in 10 Americans said they were aware these treatments exist. That is broad exposure, not a niche cure. When usage moves that sharply and awareness is this wide, the market signal is hard to ignore.

Consumer demand quickly showed up in the numbers

That consumer signal turned into financial results fast. In the first quarter, Lilly posted revenue of $19.8 billion, up 56%, and management raised its full-year revenue outlook to $82.0 billion to $85.0 billion. In plain English, demand was real, and it flowed through to revenue and guidance.

Now the next checkpoint is here. Lilly reports next week on August 5, in the first full quarter with sales from newly launched oral obesity drug Foundayo. That is the why-now: investors get a fresh read on whether demand is still climbing. Bulls see continued execution against a high bar; bears see a stock with consensus EPS of roughly $8.81 and high expectations already built in. Strong demand is clear. The debate is whether it is still strong enough for investors paying up.

The good news is simple: this was not balance-sheet magic. Lilly's first-quarter surge was primarily driven by volume growth, even though management noted lower realized prices from Mounjaro and Zepbound. That matters. A quarter can look stronger for a while through accounting adjustments, but sustained prescriptions and patient uptake are harder to fake.

Mounjaro and Zepbound did the heavy lifting

Look at the products, not just the paperwork. Mounjaro revenue rose 125% to $8.66 billion in the first quarter, and Zepbound posted $4.16 billion in U.S. revenue, up 80% from the year-earlier period. Those results support a straightforward conclusion: the core drugs kept gaining traction even as pricing conditions softened in the U.S.

That is also why Lilly could still raise its full-year sales outlook despite price pressure. The operating mechanism is simple enough: patients wanted the drugs, demand held up, and volumes were strong enough to help offset weaker U.S. pricing.

The stock now has to justify the premium

The debate from here is not whether Lilly has a real business engine. It is whether that engine can still support an expensive stock when the easiest proof point is already visible. Lilly reports next week on August 5, in the first full quarter to include sales from newly launched oral obesity drug Foundayo. Consensus sits around revenue of approximately $20.5 billion and EPS of roughly $8.81. That is a demanding bar.

Bulls will argue Foundayo is the next leg: a pill format could widen the customer base beyond injectables and help Lilly defend its lead as the market gets more competitive. Bears will argue the bar is simply too high and the margin for error is thin. Either way, investors are no longer paying only for discovery. They are paying for continued execution.

What the August 5 report actually needs to show

The key question on August 5 is not just whether Lilly beats estimates. It is whether Foundayo is doing at least an acceptable job and whether Mounjaro and Zepbound are still carrying the load.

If those checks pass, the story can keep working. If not, the market may stop treating Lilly like a sure thing and start treating it more like a great business facing tougher math.

What investors should watch before chasing the stock